TRDA vs V · P/E 12, rev $210.8M vs P/E 33, rev $40.00B
Entrada Therapeutics Inc (TRDA) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
TRDA currently screens at market cap $274.4M and trailing P/E 12.5. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the TRDA and V stock pages for the full models.
Not investment advice.